IP Library Granted Patent US 11,247,981
Granted Patent B2
US 11,247,981 · App. 16/735,094 · Granted Feb 15, 2022

Metalloenzyme inhibitor compounds

Inventors: William J. Hoekstra (Durham, NC); Robert J. Schotzinger (Raleigh, NC); Stephen W. Rafferty (Lake Worth, FL)
Assignee: Mycovia Pharmaceuticals, Inc.
C07D401/06A61K45/06C07F9/6524C12N9/0073
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,247,981
App. No.
16/735,094
Granted
Feb 15, 2022
Kind
B2
Abstract

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

Claims (41)

1. A method of treating a subject suffering from or susceptible to a disorder or disease, wherein the subject has been identified as in need of treatment for the disorder or disease, comprising administering to said subject in need thereof, an effective amount of a compound of Formula I,

or salt thereof, wherein:

MBG is tetrazolyl;

R 1 is halo;

R 2 is halo;

R 3 is independently halo, haloalkoxy, haloalkoxyalkyl, or hydroxyl;

R 4 is aryl, optionally substituted with 0, 1, 2 or 3 independent R 3 ;

R 5 is H or —P(O)(OH) 2 ;

R 6 is H or halo; and

n is 0, 1, 2 or 3.

2. The method of claim 1 , wherein the disorder or disease is associated with one or more of the following pathogenic fungi: Absidia corymbifera, Ajellornyces dermatitidis, Arthroderma benhamiae, Arthroderma flavum, Arthroderma gypseum, Arthroderma incurvaturn, Arthroderma otae, Arthroderma vanbreuseghemii, Aspergillus flavus, Aspergillus fumigates, Aspergillus niger, Blastomyces dermatitidis, Candida albicans, Candida glabrata, Candida guilliermondii, Candida krusei, Candida parapsilosis, Candida tropicalis, Candida pelliculosa, Cladophialophora carrionii, Coccidioides immitis, Cryptococcus neoformans, Cunninghamella sp., Epidermophyton floccosum, Exophiala dermatitidis, Filobasidiella neoformans, Fonsecaea pedrosoi, Fusarium solani, Geotrichum candidum, Histoplasma capsulatum, Hortaea werneckii, Issatschenkia orientalis, Madurella grisae, Malassezia fur, Malassezia globosa, Malassezia obtusa, Malassezia pachydermatis, Malassezia restricta, Malassezia slooffiae, Malassezia sympodialis, Microsporum canis, Microsporum fulvum, Microsporum gypseum, Mucor circinelloides, Nectria haematococca, Paecilomyces variotii, Paracoccidioides brasiliensis, Penicillium marneffei, Pichia anomala, Pichia guilliermondii, Pneumocystis carinii, Pseudallescheria boydii, Rhizopus oryzae, Rhodotorula rubra, Scedosporium apiospernium, Schizophyllum commune, Sporothrix schenckii, Trichophyton mentagrophytes, Trichophyton rubrum, Trichophyton verrucosum, Trichophyton violaceum, Trichosporon asahii, Trichosporon cutaneum, Trichosporon inkin, Trichosporon mucoides.

3. The method of claim 2 , wherein the compound is 2-(2,4-Difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol.

4. The method of claim 2 , wherein the compound is (+)-Difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol.

5. The method of claim 1 , wherein the disorder or disease is Aspergillosis, Blastomycosis, Candidiasis, Chromomycosis, Coccidioidomycosis, Cryptococcosis, Dermatophytoses, Histoplasmosis, Keratomycosis, Lobomycosis, Malassezia infection, Mucormycosis, Paracoccidioidomycosis, Penicillium marneffei infection, Phaeohyphomycosis, Pneumocyctis pneumonia, or Rhinosporidiosis.

6. The method of claim 5 , wherein the compound is 22-(2,4-Difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol.

7. The method of claim 5 , wherein the compound is (+)-Difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol.

8. The method of claim 1 , wherein

R 1 is fluoro;

R 2 is fluoro;

R 3 is haloalkoxy or haloalkoxyalkyl;

R 4 is phenyl substituted with 1, 2, or 3 fluoro;

R 5 is hydrogen;

R 6 is hydrogen; and

n is 1.

9. The method of claim 8 , herein R 2 is fluoro.

10. The method of claim 9 , wherein R 1 and R 2 are fluoro.

11. The method of claim 1 , wherein R 1 is fluoro.

12. The method of claim 1 , wherein wherein R 3 is haloalkoxyalkyl or haloalkoxy, and n is 1.

13. The method of claim 12 , wherein wherein R 3 is 2,2,2-trifluoroethoxy, and n is 1.

14. The method of claim 1 , wherein wherein R 4 is phenyl optionally substituted with 0, 1, 2, or 3 independent halo.

15. The method of claim 14 , wherein wherein R 4 is phenyl optionally substituted with 2 halo.

16. The method of claim 15 , wherein wherein R 4 is phenyl substituted with 2 fluoro.

17. The method of claim 1 , wherein wherein R 5 is hydrogen.

18. The method of claim 1 , wherein wherein

R 1 and R 2 are fluoro;

R 3 is 2,2,2-trifluoroethoxy and n is 1;

R 4 is difluorophenyl; and

R 5 and R 6 are hydrogen.

19. The method of claim 1 , wherein the compound is 22-(2,4-Difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol or 2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-yl dihydrogen phosphate.

20. The method of claim 1 , wherein the compound is 22-(2,4-Difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol.

21. The method of claim 1 , wherein the compound is (+)-2-(2,4-Difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol.

Continuity (4)
Continuation 16259096 · Jan 28, 2019
Continuation 14373314
Provisional Application 61589076 · Jan 20, 2012
Related Publication 20200247779A1 · Aug 6, 2020